The Ohio Bioscience Growth Report is published by BioOhio, the state’s bioscience organization, to inform the public on the progress of Ohio’s bioscience industry, research endeavors, and community at large.
The report presents factual findings analyzing the bioscience sector within the state and its six geographic regions. To present content relevant to the full continuum of bioscience in Ohio, information is provided on the six core subsectors as well as critical contributors to the industry. All of these sectors have a common goal, to improve the quality of life for our community.
- Agricultural Biotechnology
- Bioscience Education in Ohio
- Healthcare & Life Science IT
- Healthcare Providers
- Medical & Testing Laboratories
- Medical Devices & Equipment
- Medical Product Distribution
- Pharmaceuticals & Therapeutics
- Research & Development
- Suppliers & Service Providers
Over 78,800 employees, the highest on record, work with at least 3,336 bioscience-related organizations, manufacturing products, providing essential services, or researching the next breakthrough at 4,165 facilities in Ohio, generating $5.83 billion of payroll at an average wage of $73,897.
The bioscience industry’s economic impact is felt throughout the state, with bioscience-related companies found in 81 of 88 Ohio counties. All six Ohio regions have experienced growth in the bioscience industry and play a role in advancing critical discoveries.
Ohio bioscience firms range from the large and well known such as Abbott, Battelle, Cardinal Health, Ethicon (a Johnson & Johnson company), Midmark, and STERIS, to young and growing companies including Abeona Therapeutics, Enable Injections, and Myonexus Therapeutics.
Bioscience companies continue to expand operations and announce new facilities in the state, with 46 projects announced in 2017, projecting creation of 5,278 jobs and over $632 million in capital investment. Abeona Therapeutics, Alkermes, CoverMyMeds, Ensemble Health Partners, Medpace, Midmark, Norwood Medical, PharmaForce, Q Laboratories, Quality Electrodynamics, RXQ Compounding, Sterigenics, Updox, West-Ward Pharmaceuticals, and Xellia Pharmaceuticals are all among the many companies that continue to grow in Ohio.
Since 2012, over 490 new bioscience-related firms began operations in Ohio, including Diasome Pharmaceuticals, Kapios Health, Myonexus Therapeutics, SapVax, ScriptDrop, Soin Neuroscience, and Xact Medical. Many existing firms, such as Inogen, Owens and Minor Distribution, Piping Rock Health Products, Pulse Flow Technologies, and RelateCare chose to locate their business in Ohio.
Ohio bioscience companies attracted over $2.7 billion in funding in 2017, from sources including venture capital, exits, angel investment, federal research grants, and state initiatives such as the Ohio Third Frontier.
Bioscience companies announced $526 million in private investment in 2017, the third highest level recorded since BioOhio began tracking deals in 2004. Exit activity in the state remained strong in 2016-17, totalling over $2.4 billion, including significant public offerings from Abeona Therapeutics, Athersys, Medpace, and ViewRay.
Bioscience education continues to thrive in Ohio with 10,179 bioscience-related degrees and certificates awarded to students in Ohio in 2015 at 102 public and private schools.
Download the full report for in-depth discussion of these progress indicators and much more. BioOhio sincerely hopes you will join us in celebrating Ohio’s thriving bioscience community.